WHEA:LSE:LSE-SPDR® MSCI World Health Care UCITS ETF (USD)

ETF | Others |

Last Closing

USD 60.23

Change

0.00 (0.00)%

Market Cap

USD 0.56B

Volume

5.84K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 642.91B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 636.40B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 330.91B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B

ETFs Containing WHEA:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.31% 48% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.31% 48% F 52% F
Trailing 12 Months  
Capital Gain 4.72% 39% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.72% 37% F 49% F
Trailing 5 Years  
Capital Gain 60.53% 75% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.53% 73% C 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 9.78% 71% C- 73% C
Dividend Return 9.78% 70% C- 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.36% 66% D+ 79% B-
Risk Adjusted Return 94.45% 97% N/A 98% N/A
Market Capitalization 0.56B 71% C- 61% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike